NCT05924477Recruiting
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 226 (estimated)
- First submitted
- 8 Jun 2023
- Start date
- 11 Jul 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Pennsylvania
- Diseases
- Glaucoma
- NCT number
- NCT05924477
What you commit to
- Study type: Interventional
- Planned participants: 226
- From 11 Jul 2023 to the primary completion date, 31 Dec 2026
- 8 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Preexisting corneal condition that would affect the corneal endothelium or previous corneal transplant
- Previous GDD, Xen Gel Stent or Preserflo MicroShunt removed less than 6 months before surgery
- Previous trabeculectomy and/or minimally invasive glaucoma surgery within the past 6 months
- Need for glaucoma surgery combined with other ocular procedures (i.e. corneal transplant, or retinal surgery) or anticipated need for additional ocular surgery
Other illness
- Presence or history of Cypass Micro-Stent
- Presence of nanophthalmos, uncontrolled uveitis, silicone oil, Sturge-Weber syndrome or other conditions associated with elevated episcleral venous pressure
Other
- Presence of GDD implantation, Xen Gel Stent, of Preserflo MicroShunt
- AC intraocular lens
- Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits
- No light perception vision in the study eye or fellow eye visual acuity \< 20/200
Who the study is looking for
- Medically uncontrolled glaucoma requiring GDD or GDD combined with phacoemulsification as the planned surgical procedure
- Candidate for GDD implantation for ciliary sulcus and AC tube
- Age greater than or equal to 18 years old
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Prism Eye Institute, University of Toronto Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| Wilmer Eye Institute, Johns Hopkins University Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
| Massachusetts Eye and Ear Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| University of Buffalo/State University of New York Coordinator of this site? Confirm its status | Buffalo | United States | Recruiting |
| University of North Carolina at Chapel Hill Coordinator of this site? Confirm its status | Chapel Hill | United States | Recruiting |
| Bascom Palmer Eye Institute Coordinator of this site? Confirm its status | Miami | United States | Recruiting |
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
| Diablo Eye Associates Coordinator of this site? Confirm its status | Walnut Creek | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.